Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings support...

Descripción completa

Detalles Bibliográficos
Autores principales: Azevedo, Rita, Peixoto, Andreia, Gaiteiro, Cristiana, Fernandes, Elisabete, Neves, Manuel, Lima, Luís, Santos, Lúcio Lara, Ferreira, José Alexandre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710962/
https://www.ncbi.nlm.nih.gov/pubmed/29207682
http://dx.doi.org/10.18632/oncotarget.19433

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710962/
https://www.ncbi.nlm.nih.gov/pubmed/29207682
http://dx.doi.org/10.18632/oncotarget.19433

Ejemplares similares